Use of type V phosphodiesterase inhibitors in the treatment of exercise induced pulmonary hemorrhage in the equine
US8217049B2 · kind B2 · utility
0Cited by
1References
10Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | May 1, 2007 |
| Grant date | Jul 10, 2012 |
| Priority date | — |
| Expiry date | May 1, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of type V phosphodiesterase inhibitors as a novel independent therapeutic modality in the treatment of exercise induced pulmonary hemorrhage in equine is described. The type V phosphodiesterase inhibitor is injected into the horse intravenously as a stand-alone agent from about one-half hour to about seven (7) days prior to the onset of strenuous exercise.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.